Eton Pharmaceuticals Out-Licenses International Rights to Increlex®

DEER PARK, Ill., April 01, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the out-licensing of commercial rights to Increlex® in territories outside of the U.S. to Esteve Pharmaceuticals, S.A. (“Esteve”).

Read more at globenewswire.com